These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15670547)

  • 21. Acute ischemic coronary artery disease and ischemic stroke: similarities and differences.
    Fisher M; Folland E
    Am J Ther; 2008; 15(2):137-49. PubMed ID: 18356634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis.
    Choudhry NK; Avorn J; Antman EM; Schneeweiss S; Shrank WH
    Health Aff (Millwood); 2007; 26(1):186-94. PubMed ID: 17211028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term safety of antihypertensive therapy.
    Grossman E; Messerli FH
    Prog Cardiovasc Dis; 2006; 49(1):16-25. PubMed ID: 16867847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The future of antihypertensive treatment.
    Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secondary prevention therapies for coronary heart disease in patients with type 2 diabetes: an audit.
    Sharma KK; Guptha S; Gupta R
    J Assoc Physicians India; 2012 Apr; 60():28-30. PubMed ID: 23029739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M; Tocci G; Sciarretta S; Verdecchia P; Trimarco B; Mancia G
    J Hypertens; 2009 May; 27(5):941-6. PubMed ID: 19381108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The role of omega-3 fatty acids from fish in prevention of cardiovascular diseases].
    Reiner E; Tedeschi-Reiner E; Stajminger G
    Lijec Vjesn; 2007; 129(10-11):350-5. PubMed ID: 18257336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secondary medical prevention among Danish patients hospitalised with either peripheral arterial disease or myocardial infarction.
    Gasse C; Jacobsen J; Larsen AC; Schmidt EB; Johannesen NL; Videbaek J; Sørensen HT; Johnsen SP
    Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):51-8. PubMed ID: 17923426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study.
    Blackburn DF; Dobson RT; Blackburn JL; Wilson TW; Stang MR; Semchuk WM
    Can J Cardiol; 2005 May; 21(6):485-8. PubMed ID: 15917876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular risk prevention in peripheral artery disease.
    Hackam DG
    J Vasc Surg; 2005 Jun; 41(6):1070-3. PubMed ID: 15944615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polypill: for Pollyanna.
    Spence JD
    Int J Stroke; 2008 May; 3(2):92-7. PubMed ID: 18706002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Secondary prevention after myocardial infarction].
    Czuriga I
    Orv Hetil; 2002 Sep; 143(37):2117-28. PubMed ID: 12434627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease.
    Hueb W; Lopes NH; Gersh BJ; Soares P; Machado LA; Jatene FB; Oliveira SA; Ramires JA
    Circulation; 2007 Mar; 115(9):1082-9. PubMed ID: 17339566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sudden death secondary to cardiac arrhythmias: mechanisms and treatment strategies.
    Siddiqui A; Kowey PR
    Curr Opin Cardiol; 2006 Sep; 21(5):517-25. PubMed ID: 16900017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
    Kumar A; Fonarow GC; Eagle KA; Hirsch AT; Califf RM; Alberts MJ; Boden WE; Steg PG; Shao M; Bhatt DL; Cannon CP;
    Crit Pathw Cardiol; 2009 Sep; 8(3):104-11. PubMed ID: 19726929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Commentary on NICE guidance for secondary prevention for patients following a myocardial infarction.
    Skinner JS; Minhas R
    Heart; 2007 Jul; 93(7):864-6. PubMed ID: 17569812
    [No Abstract]   [Full Text] [Related]  

  • 37. Primary prevention of myocardial infarction: putting the evidence to use.
    Herzog E; Javed F
    Arch Intern Med; 2010 Aug; 170(15):1381-2. PubMed ID: 20696965
    [No Abstract]   [Full Text] [Related]  

  • 38. [Stable coronary artery disease--invasive treatment does not replace secondary prevention].
    Kettunen R; Lepojärvi M; Laine M
    Duodecim; 2012; 128(7):720-7. PubMed ID: 22612022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular disease prevention using fixed dose pharmacotherapy in Iran: updated meta-analyses and mortality estimation.
    Sepanlou SG; Farzadfar F; Jafari E; Danaei G
    Arch Iran Med; 2012 Sep; 15(9):531-7. PubMed ID: 22924369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secondary prevention for ischemic heart disease. Relative numbers needed to treat with different therapies.
    Miller DB
    Arch Intern Med; 1997 Oct; 157(18):2045-52. PubMed ID: 9382659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.